What we’re looking for
The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for mental health conditions, in particular:
- psychotic disorders
- affective disorders
- cognitive disorders
- psychiatric symptoms associated with dementia
The Psychiatry Consortium intend to fund projects which:
- are supported by robust evidence that links the molecular target to human disease, which can be further developed or validated,
- provide a sound therapeutic hypothesis of how target modulation may have a therapeutic effect,
- will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability
Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.
A key priority for us whilst reviewing applications is whether proposals are supported by robust evidence linking the molecular target to human disease and of target modulation having a therapeutic effect. The Psychiatry Consortium is perfectly positioned to support researches further develop or validate this initial package of evidence.
Applications which are supported by robust evidence that links the target to the human condition, and provide a sound therapeutic hypothesis of how target modulation may have a therapeutic effect stand the best chance of success.
Our funding is open to universities, research institutes and small companies (micro and medium) worldwide.
Projects are expected to last up to 2 years, with total project costs between £150,000 – £600,000.